Charlty number: 1181623 BRITISH SOCIETY OF ENDOVASCULAR THERAPY UNAUDITED TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 Armstrongwatson. Accountants, Business & Financial A(fvisers
BRITISH SOCIEfY OF ENDOVASCULAR THERAPY CONTENTS Page Reference and administratlve details of the Charity. its Trustees and advisers Trustees. report Independent examiner's report Statefflent of financial activitles Balance sheet Notes to the flnancial statements 9-16
BRITISH SOCIEfY OF ENDOVASCULAR THERAPY REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY. rrs TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 JANUARY 2025 Trustees Professor B Modarai. Trustee Mr S Neequaye, Trustee Mr P Bems. Trustee Mr P Moxey. Trustee Mr D Bosanquet. Trustee Mr A Sarats"s, TTUStee (Resigned 28 June 2024) Ms E Wilton. Trustee Mr M Claridge, Trustee Ms B Sandford, Trustee Dr K Lews, Truslee Dr S Dindyal, Trustee Dr A Wigham. Trustee Mr N Daltani, Trustee Miss K Sritharan. Trustee Mr A Patel, Trustee (appointed 28 June 2024) Mr S Nandhra. Trustee (appointed 28 June 2024) Mr J Mccaslin. Tnjstee lappointed 28 June 20241 Charity reglstered number 1181623 Accountants knstrong Watson LLP Cadeton House 136 Gray Street Workington Cumbria CA14 1LP Page 1
BRITISH SOCIETY OF ENDOVASCULIR THERAPY TRUSTEES. REPORT FOR THE YEAR ENDED 31 JANUARY 2025 The Trustees present their annual report together Vth Ihe financial statements of the Charity for the year 1 Febnjary 2024 to 31 January 2025. Oblectlves and activities a. Pollcies and objectives The British Society of Endovascular TherapS primary role is to promote the best in research. training, education and clinical practice for the benefft of people medical conditrons tho could potentially be helped by endovascular therapies. It achieves this wth the fdlowng aims.. 1) to advance health by promoting scientific research. education and training in endovascular treatment and procedures,. and 21 to advan the education of the wblic and paCulaY amongst health professionals in endovascular treatment and procedures The Society continues its commitment to improving the qualty of endovascular surgery in the UK through its training courses, Annual Meets"ng, and Training and Research Feifowships. The BSET meeting is the only dedicated UK meeting for the presentation of endovascular research. Its unique fomial encourages high level discussion and participation and the meeting faculty attracts the world's leading endovascular spectalists. The Society's trustees have complied the duty in sects.on 4 of the Charities Act 2011 to have due regard to Public Benefft guidance published by the Charity Commission. Achievements and performance a. Educatlon and Tralning The Sociews Annual Meeting was held in June 2024. The meeting attracted over 120 endovascular consultants, trainees and allied medical professionals. The prcKJramme comprised presentations from guest speakers from the USA, Italy, and the Netherfands, with abstract and poster presentations from endovascular trainees in the UK. The Society awards a prize for the best presented abstract in the Aortic Prize Session and Peripheral Pr¢ze Session. as well as for the best poster presentatson al the Annual Meeting. A National Vascular Training Day was hekl pr to the Annual Meeting for 36 junh?r endovaseular trainees comprising srnall case based discussion groups and pfdth.cal hands-on training on endovascular devices. The BSET Endovasujlar Training Gr5e was held in March 2024 for senior vascular and interventional radiolc%Jy trainees. Attendees were taught in small group sessions looking at the finer points of endovascular treatment alongside industrystho provided hands-on prath.cal training on surgical dewces. The BSET Training Courses and Annual Meeting are well received by attendees. particulady endovascular trainees. Feedback received from the Annual Meeting includes comments that the programme content was of a high standard,. Ihal the meeting provides an excellent opportunity to get up to date practice infomialion and new guidelines.. and that it allows individuals to focus on ongoing research and training for the benefit of patients. Attendees at the Society Training Courses found that they were well structured with opportunities for peer discussion offering the greatest leaming value. In particular, attendees found that the facultys expertise and the presentations were of the hhe$l standard. offering insighfful and well-stnjclured content that was dinically levant. The BSET Feilowship Programme a$ adverb.sed for 2024 arKI one Endovascular Training Fellowship was appointed who 11 undertake a six month training post at Addenbrcx)ke's Hospital, Cambridge. The Training Fellowship provides an opportunrty for vascular or intervenb'onal radiol¢)Jy trainees to acqui new or more complex endovascular skills. Page 2
BRfTISH SOCIEfY OF ENDOVASCUL*A THERAPY TRUSTEES. REPORT {CONTINUEDI FOR THE YEAR ENDED 31 JANUARY 2025 Achievements and performance (continued) Two Endovascular Travel Fellows were appointed. and funding was given lo support further training in specialist endovascular units in Germany and Italy. AII BSET Fellows provide a written report of their Fellowship experience which is made available on the Sociews website, and also attend the Annual Meeting to give a presentation to attendees. b. Research BSET is committed to driving excellence in research and improwng outcomes for patients by raising the profile and impact of endovascular research. Two Research Pump Priming Grants were awarded for the first time in 2024 lo support research projects in the field of endovascular therapy. The BSET-ConformabLe Endovascular AneUrn Registry. on behalf of Gore. commenced in 2019. The primary objective of the registry is lo collect real-worfd clinical data and device specific outcomes of GORE EXCLUDER Confomiable AAA Endoprosthesis in routine dinical treatment of patients with abdominal aortic aneurysms. Al data checks on 12 month follow-up clinical data have been analysed and a manuscript "An analysis of aortic neck coverage of the GORE@ EXCLUDER@ Conforvnable AAA Endoprosthesis with ACTIVE CONTROL System,. has been accepted for publication in the Joumal of Endovascular Therapy. BSET has supported new research evaluatrng long-temi outcomes1>10 years) for FEVAR from GLOBALSTAR registy data (Global Collabordlots on Advanced Slent-Graft Technbques for Aneurysm Repair). The registry originally contained 881 records from 15 collaborating centres. The aim of the present study is to complete long- term follow-up for GLOBALSTAR by collects.ng new dats and bolstering study numbers through the contn"bution of new retrospective cases accrue(I follow-up dats from participatsng centres. The ethical approval for GLOBALSTAR was renewed by the current study team. The team is led by Chief Investigator for GLOBALSTAR, Mr Simon Neequaye (Trustee) and clves"gat0r Mr Aurélien Guéroult at St George's Hospital. The co- investigator has come out of programme for a doctoral thesis. The hospitsl agreed to meet the cost of this and so the Tnistees agreed that the funds sel aside as restricted for Globalstar could now be made unrestricted funds. Any expenses incurred to support the work of the researcher wwld be paid for from these funds. The project has benefited from patient involvemenvfeedback Ihrough the St George's Vascular patient advisory group. Upon integration of the final centre's dalaset. manuscript ting wll begin. Results will be disseminated through academic conferences and the data will be presented at the Annual Meeting in June 2025. It is hoped that publicab.on of the final dats wll positively influence commissioning decisions wlhin the NHS. c. Collaborative work Discussions had taken place wth the Brish Scciety of InteNentional Radiology wth the aim to fomi a closer relationship between BSET and BSIR. A stalement of collaboration was produced and an agreement made to have an educational session at the BSIR Annual Meeting. It was also agreed to pursue a joint educational webinar. The Trustees were working the charity The Circulation Foundation to assist an update on their patient information leaflets relating to endovascular treatment. Page 3
BRrrisH SOCIEfY OF ENDOVASCULAR THERAPY TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 31 JANUARY 2025 Achievements and perfomiance (continued) d. Structurei governance and management Two Trustee meekn.ngs were held in person and iwo OTr&line during this pericml. Organisational matters were dealt with via email. The Trustees had agreed lo Introdu a new role of Wice-President. The Ifice-President was elected in June 2024 and commenced a one year lead-in period prior to tsking on the role as President for Iwo years from June 2025. This position is open to all premous and current Council members of BSET. Two new Trustees were elected in June 2024. The Trustees continued lo diseJJss the need for a piCY on equalty. diversty and inclusion and work was continuing on this. e. Aims and key objectives for futhre I10d$ The Trustees plan to continue lo hdd the Endovascular Training C(MJrse in March 2025. and also hold the Annual Meeting and National Vascular Training Day in June 2025. Consideration would be given to extending the length of the Annual Meeb'ng. An Endovascular Training Fellowship and Travel Fellowshipls) will be offered in 2025. Consideration would be given lo increasing the amount awarded for a Travel Fellowship. A Research Pump Priming Grant wll be awarded to support a research project in the field of endovascular therapy. Consideration would be given to increasing the level of the grant the option of awarding up to grants. The Trustees wll conb.nue lo work the charity The circulats.on Foundation to update their patient information leaflets relating to endovascular treatment. Discussions wll conb.nue wth the 8ritish Swety of Interventional Radiology the aim to form a closer relationship beeen BSET and BSIR to invdve increased parttupation of Society memt*rs at both meetings and increased dialogue. Financial revlew a. Reserves policy The SocietYs reserves policy is maintained at £280.000. This WTII allow BSET to keep approximately 2 years. annual operating costs in reseNe. The Trustees wll continue to assess the level of reserves il requires and will update the policy rf it is felt its financial requirements have changed. The reserves policy ensu$ unrestricted funds are sufficient to meet tsvo years. actmty of the Society. to cover: a) The risk of unforeseen emergency or other unexpected need for funds. e.g. to prowde 'seed-funding' for an urgent project. bl Unforeseen day-to4ay Operaon81 Costs. e.g. employing temporary staff to cover a long-temi sick absence. cl A source of income, e.g. a sponsorship of our meetings. not being renewed. Funds might be needed to give the tnjstees time to tske action if income falls below expectstions. dl The need to fund short-term defitits in a cash budget, e.g. money may need to be spent before a funding grant is received. Page 4
BRifisH SOCIETY OF ENDOVASCULAR THERAPY TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 31 JANUARY 202S StrnCtu, governance and management a. Methods of appoinlm8llt or election of TnBtees Every Iruslee is appointed for a teim of Ihree year5. In selecting indiwduals for appointment, the charity trustees must have regard to the skills. knovledge and experience needed for the effeCve adrninistration of the CIO. Individuals are requested to submit a 200 word personal ststemenl tsuuining why they wsh to act as a charity trustee. All new trustees 3re asked to sign a statement of eligibility and are se*)t the fo110Yng". The charity""s conskniution The minutes of Council meetings for the prev40us year. List of Current trustees and contact details". Annual list of dates of trustee meetings.. The Tnost recent Chanty accounts". A copy of the Charrty CoTnrnissI publication The Essenb"al Trustee-what you need to knov/." There are four trustee Icouncdl meeling5 a year at which Cfjeraknonal and finan¢5al matters of the Society are discussed, and strategic decisions ab(rt Ihe direction of the charity are taken. In bebpfftn meetings, decisions are made by tdephone or e-mail communication betsn the Honorary Officers and other trustees. An administrator working on a con5ultanty basi5 deals th matters pertaining to the general organisation of the Souety. Annual Meeting and otheT events. BSET has c(1&boratIVe link5 Ihe Royal College of Surgeon5 (Engl, Royaj College of Svrgeons (Edl, the Vascular Society ot Great 8fitain 3n¢J Ireland. the Rouleaux Club. Ihe Britssh Society of Interventional Radiology. and the BSIR Trainees to help further the aims of the developing specialrty and to deliveT high standards of practice. Approvetj by o er ofthe member5 of the board of Twstees and signed on thelr iEhalf by". Professor B Modarai Mr P Bevis Date." 25 June 2025 Page 5
BRrrisH SOCIETY OF ENDOVASCUiAR THERAPY INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31 JANUARY 2025 IndÈper¥dent exarninerfs rnport to th• TnBtes of British Society ol Endovascular Therapy I'the Charity'l I report to the Charity Trustees on my examin. of the accounts of the Charity for the year ended 31 January 2025. Responstbilitles and l)asis of report As the Trustees of tre Charity you are resr¥)nsible for the rxeparation of the arUnts accordarKe the requirements of the Charits"es Act 2011 (Yhe 2011 Acri. I report in respect of my examination of the Chairws 8fits caryied out under section 145 of the 2011 Act and in carying out my examination I have fo)wed the apptic8ble Dire¢trons gNen by the Charity Comrnission under section 145lSllbl of the 2011 Act. Independent examins ststement Your attention is drawn to the fact that the Charity has prepare(f the ac£wnts in ac£ordance wth ArKounting and Reporting by Charities: Statement ol Recommefjded practi applicable to chartbes preparing their accounts in accordance Vth the Financial Reporting Standard applicable in the UK and Republic gf Ireland IFRS 1021 in preference to the Accounting and Reporting by Charibes.. Siaternent ol Recommended Pract"cE issued on 1 Apnl 2005 which ts referred to in the extant regulations but has been wthdravm. l understan¢J that this ha5 been done in orrjer for the acrAwnts to wo¥wJe a true and fair Mew in accordance the Generally Accepted Accounting Practice effective frjr repotbng perirxls beginning on or after 1 January 2015. I have completed my examination. I confinn trAt r matters have corne to my attention in connection with the examination g5w7ng me cause to believe that in ary matwial respect.. accounting ietords were not kept in respect of the Charity as requi by section 130 of the 2011 Actr. or the accounts do not aceord those records," ¢ the accounts do not the applicable requirernents con¢eming the form and content of accounts set ¢JJt in the Charities (Accounts and Reports) Regulab"ons 2008 other than any QUIreMent that the accounts give a Irue and fairf view is Mt a matter Tr)n&dered as part of an independent examination. I have no eoncems and have come across no Other matters in connection the examination to which attention should be drawn in this report in order to enable a proper understanding of the acewnts to be reached. Signed.. Dated. 11.61. IJ BFP FCA ATT MAAT Steven TrQrkbride Amistrong Watson LLP. Workington Page 6
8RmsH SOCI OF ENDOVASCULAR THERAPY STATEMENT OF FINANCIAL ACTJVITIES FOR THE YEAR ENDED 31 JANUARY 2025 Unrestricted Restricted funds funds 2025 2025 Total funds 2025 Total nds 2024 NolÈ In¢ome from: Donstions and aCleS other trading athibes Investments 35,988 35,988 166,571 956 68,964 294,644 166.571 othef ineome 30.998 30.998 26,299 Total income 194525 35.988 234,513 389,907 Expenditure on: Chafitabie activities 164,551 775 165,326 3qO,609 Total exp8ndiiure 164551 775 165.326 310,609 Net income 33,974 100.644 35,213 1100.6441 69.187 79,298 Transfers between funds 10 Net mov8mont in funds 134618 165.4311 69,187 79.298 Reconclllatlon ol funds= Total funds brought forward Net movement in funds 374100 134.618 65.431 165.4311 439,531 69,187 360,235 79,298 Totsl [ts Carried foTh¥ard 508.718 508,71B 439.531 The Statement of firncral actswbes wJude5 all gatns and losses recognis in the year. The notes on pages 9 to 16 lomi part of these financi stateMls. Page 7
BRtrisH SOCIETY OF ENDOVASCULAR THERAPY BALANCE SHEET AS AT 31 JANUARY 2025 2025 2024 Note Flxed assets Current asset5 Cash at bank and in hand 510.398 441,061 510,398 441,061 Creditors." amounts falling Ilue bslthin one year 11,6801 {1,530J Net Gurrent assets 508,718 439.531 Total assets less current liabilities 508,718 439.531 Net assets excluding pension asset S08,718 439.531 Total net assets 508.718 439,531 Charity lunds Restricted funds Ullre5tricted funds 10 10 65,431 374, 100 508,718 Totsl funds 508.718 439.531 The financial statements we approved 3nd aulhorise(I iswe by the Trustees and signed on Ihesr behalf by." Profes Mr P Bevis Date." 25 June 2025 The notes on pages 9 to 16 form part of these financial 5t3tements. Page 8
BRrfisH SOCIEfY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 General infomiation British Society Of Endovascular Therapy is a charitable incorporated organisation. Accountlng policies 2.1 Basis of preparation of financial statements The finanrial statements have been prepared in accordance vith the Charitieg SORP IFRS 1021- Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reports'ng Standard applicable in the UK artd Republic of Ireland IFRS 102) {effective 1 January 20191, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 1021 and the Chariknes Act 2011. The financial $12tements have been prepared to give a ITue and fairf view and have departed from the Charities {Accounts and Reports) Regulakn"ons 2008 onty to the extent required to provide a Irue and fairf view. This departure has involved followsng the Charities SORP IFRS 1021 published in October 2019 rather than the Accounting and ReFKJrting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been wthdravm. British Society of Endovascular Therapy meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised al histOTical cost or transaction value unless otherwise staled in the relevant accountyng policy. 2.2 Going concern At the time of approving the financial statemenls, the trustees have a reasonable expectation that the charity has adequate resour$ to continue in operational existence for the foreseeable future. Thus the tnistees continue to ad1 the going concern basis of accounting in preparing the financial statements. 2.3 Inme l income is recc•3nised once the Charity has ents"tSement to the income. it is probable that the income wll be recewed and the amount of income recebvable can be measured lIablY. Other income is recognised in the period in which it is receivable and to the extent the goods have been promded or on ciwnpletion of the serwce. 2.4 Expenditure Expenditure is recognised once there is a legal or constnjctive obligation to transfer economic benefit to a third party. it is probable that a transfer of economic benefits wll be required in settlement and the amount of the obligab.on can be measured reliably. Expenditure is classffied by activity. The costs of each activity are made up of the total of direcl costs and shared costs. including support costs involved in undertaking each actiwty. Direct costs attributable to a single actimty are allocated direcuy to that actiirity. Shared costs which contn.bute to more than one actiwty and support costs which are not attributable to a single activity are apportioned beh¥een those aclivities on a basis consislenl wth the use of resources. Central stsff costs are allocated on the basis of time spent, and depreciation charges allocated on the )On of Ihe asset's use. Expenditure on charitable actmbes is incurred on directly undertaking the activities which further the Charitys objectives. as well as any associated support costs. All expenditure is indusive of irrecoverable VAT. Page 9
BRrfisH SOCIEfY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 Accountlng policies (continued) 2.5 Taxatlon The Charity is considered to pass the tests sel out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definiti.on of a charitable o)mp8ny for UK corporation tax purposes. Accordingly, the Charity is potentially exempt from taxation in respect of income or capital gains received wlhin categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purFM)ses. 2.6 Cash at bank and in hand Cash al bank and in hand indudes cash and short-temi highly liquid investments with a Short maturity of three months or less from the date of acquisits or opening of the deposit or similar accounL 2.7 Liabilitles and provlsions Liabilities are recognised then there is an r*)ligation at the Balance sheet date as a result of a past event. it is probable that a transfer of economic benefft will be required in settlement, and the amount of the setdement can be estimated reliably. Liabilities are recognised at the amtyjnt that the Charity anticipates il wll pay to settle the debt or the amount il has ceiVed as advanced payinents for the goods or seNces it musl provide. Provisions are measured at the best estimate of the arnounts required lo settle the obligation. Vvhere the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-lax discount rate that reflects the risks specific to the liability. The unwnding of the discount is recognised in the Statement of finanual activits.es as a finance cost. 2.8 Financlal instruments The Charity only has financial assets and financial liabiltties of a kind that qualify as basic financial instruments. Basic financial instNments are initially recognised at transaction value and subsequently measured at their settlement value the exception of bank loans which are subsequently rneasured at amorbsed cost using the effective interest method. 2.9 Fund accounting General funds are unrestricted funds which are available for use at the discretion of the Tnjstees in furtherance of the gener81 objectives of the Charity and bthich have not been designated for other purposes. Restricted funds are funds sthich are lo be used in accordan with specific reslriclions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such fvnds are charged against the spectfic fund. The aim and use of each restricted fund is set OLrt in the notes to the finanaal statements. Investment income, gains and losses are allorated to the appropriale fund. Page 10
BRITISH SOCIETY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 Income from donations and legacies Restrlcted funds 2025 Total funds 2025 CLEVAR income 35,988 35,988 Restricted funds 2024 Tol81 funds 2024 CLEVAR income 68,964 68,964 Income from other trading activities Income from fvndraising events Unrestricted funds 2025 Total funds 2025 Annual meeting registration Sponsorships 44,571 122,000 44.571 122,000 166,571 166,571 Unrestricted funds 2024 Tot81 funds 2024 Annual meeting registration Sponsorships 38,644 256,0(K) 38,644 256,0(R] 294.644 294.644 Page 11
BRrrisH SOCIEfY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 Investment Income Unrestrlcted funds 2025 Total funds 2025 Total fvnds 2024 Investment inccKne 956 956 other Incoming resources Unrestrided funds 2025 Total funds 2025 Spring course ineome Other income 28.557 2,441 28.557 2,441 30,998 30.998 Unresliicted funds 2024 Total funds 2024 Spring course income Other income 24.595 1,704 24.595 1. 704 26,299 26,299 Analysls of expendlture by activltles Activities undertaken direcuy 2025 Total funds 2025 Charitable activities 165.326 165,326 Page 12
BRITISH SOCIETY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 Analysis of expenditure by actlvities (continued) Activities undertaken directly 2024 Total funds 2024 Charitable ackn"vibes 310,609 310,609 Analysis of direct costs Total funds 2025 Actlvlties 2025 Annual rneeling costs Sundry expenses Travel and subsistence Spring course expenditure Accountancy fees Consultancy fees Bank charges Postage. printing and stationery Prizes and bursaries 94.402 1,736 1,752 15.996 1,840 26,883 165 1,177 600 94,402 1.736 1.752 15,996 1.840 26.883 165 1,177 600 Fellowship Pump priming award expenditure GIDbalstar expenditure 10,000 10.000 10.000 10,000 li 775 775 165,326 165,326 Page 13
BRrrisH SOCIEfY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 Analysls of expendlture by activities (continued) Analysls of direct Costs (continued) Total ftjnds 2024 Activities 2024 Annual meeting costs Sundry expenses Travel and subsistence Spring course expenditure Accountancy fees Consultancy fees Bank charges Postsge. printing and slationery Prizes and bursaries CLEVAR expenditure Fellowship Globalstsr expenditure 105.837 3,271 1,309 38.354 1,608 28,359 133 105,837 3.271 1,309 38,354 1,608 28.359 133 566 688 75,498 54,481 505 566 75,498 54.481 505 310,609 310,609 Trustees. remuneration and expenses During the year, no TTUStees received any remuneration or other benefrts (2024- £NILJ. During the year ended 31 January 2025, no Trustee expenses have been incurred (2024- £NIL). Creditors: Amounts falling due wlthin one year 2025 2024 Accruals and deferred income 1,680 1,530 Page 14
BRITISH SOCIEfY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 10. Statement of funds Statement of funds - current year Balance at 1 February 2024 Balance at Transfers 31 January inlout 2025 Income Expenditure Unrestricted funds General Funds- all funds 374.100 198.525 {164.551) 100.644 508.718 RestrIed fund5 BSET CLEAVAR Globalstar 17,736 47.695 35.988 (53.724) (46,920) {775) 65,431 35,988 1775) (100.6441 Total of funds 439,531 234.513 (165.326) 508,718 Statement of funds- prlor year Balance al 1 February 2023 Balance al 31 January 2024 Income Expenditure Unrestricted funds General Funds - all funds 287. 763 320,943 (234,606) 374.100 Restricted funds BSET CLEVAR Globalstar 24,270 48,2(X) 68,964 (75,498) (505) 17,T36 47.695 72.470 68.964 (76,003) 65,431 Total of funds 360,233 389.907 (310,609) 439,531 Page 15
BRtfisH SOCIEfY OF ENDOVASCULAR THERAPY NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 11. Anatysis of net assets between funds Analysis of net assets between funds- current Fwiod Unreslrided Restricted funds funds 2025 2025 Total funds 2025 Current assets Creditors due wthin one year Drfference 456.674 (1,680) 53.724 53.724 510,398 (1,6801 153,7241 Total 508,718 508,718 Analysls of net assets between funds - ptior perfod Unrestricted fvnds 2024 RestncteLI funds 2024 Total funds 2024 Currenl asgets Creditors due wthin i)ne year 375,630 (1.530) 65,431 441,061 (1.530) Total 374, 100 65,431 439,531 12. Related party transactions The Charity has not entered into any related party transaction during the year. nor are Ihere any outstanding balances owng between related parties and the Charity al 31 January 2025. Page 16